MGZ
Medizinisch Genetisches Zentrum

2026

Validation structures for sequence variants of uncertain significance in hereditary cancer.
Lucas MC, Keßler T, Benet-Pagès A, Holinski-Feder E, Laner A, Klink B.
https://pubmed.ncbi.nlm.nih.gov/41807735/

2025

Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics.
Sauer M, Lucas MC, Prokosch V, Keßler T, Risch T, Laner A, Henkel J, Benet-Pagès A, Hallermayr A, Steinke-Lange V, Holinski-Feder E, Klink B.
https://pubmed.ncbi.nlm.nih.gov/41347847/

A series of reviews in familial cancer: genetic cancer risk in context variants of uncertain significance in MMR genes: which procedures should be followed?
Lucas MC, Keßler T, Scharf F, Steinke-Lange V, Klink B, Laner A, Holinski-Feder E.
https://pubmed.ncbi.nlm.nih.gov/40317406/

2024

Liquid Biopsy bei hereditärer Tumorprädisposition.
Hallermayr A, Keßler T, König C, Steinke-Lange V, Holinski-Feder E.
coloproctology 46, 110–115 (2024). https://doi.org/10.1007/s00053-024-00779-9

2023

The utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders.
Hallermayr A, Keßler T, Steinke-Lange V, Heitzer E, Holinski-Feder E, Speicher M.
https://pubmed.ncbi.nlm.nih.gov/38835734/

Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays.
Hallermayr A, Keßler T, Fujera M, Liesfeld B, Bernstein S, von Ameln S, Schanze D, Steinke-Lange V, Pickl JMA, Neuhann TM, Holinski-Feder E.
https://pubmed.ncbi.nlm.nih.gov/37894392/